Oncology and Hematology - Global Oncology Academy

Episodes 209-224 of 463

Management of HR+, HER2- High-Risk EBC
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
1.25 program credits
- Alan Venook, MD
1.25 program credits
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
1.25 program credits
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 program credits
Emerging Treatment Approaches for EBC
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
1.25 program credits
- Alan Venook, MD
1.25 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
1.50 program credits
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Project Oncology®
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
- Ben Park, MD, PhD
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits

14/11